Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric AGvHD
No-moat Mesoblast Ltd (MSB AU) achieved a financial milestone in the first six months of fiscal 2018 by posting a maiden net profit after tax of...
172 Views
Human Longevity
At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...
771 Views
Aussie Healthcare Daily: 8 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
284 Views
Aussie Healthcare Daily: 5 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
240 Views
Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging
We are raising our fair value estimate to AUD 2.80 per share from AUD 2.30 for no-moat Mesoblast Ltd (MSB AU), following the encouraging interim...
199 Views